ARTICLE SUMMARY:
As US medtech ponders its recovery from the COVID-19 pandemic, there are lessons to be learned from the early days of China’s rebound.
The first COVID-19 laden earnings season goes into full gear in early May, as companies report first-quarter results. Most US-focused companies only started to see notable damage from COVID-19 in mid-to-late March, so the numbers they report won’t reflect the depth of the damages. The consensus among experts is that medtech will take a much bigger hit in Q2, given the drop off in elective procedures.
